MORE►
sponsored by Munck Wilson Mandala, LLP
biotechnology
Merritt D. Westcott [Photo: via MWM]
Munck Wilson Mandala Names Merritt D. Westcott Chair of Firm’s Expanding Life Sciences Practice
by Munck Wilson Mandala, LLP | Oct 21, 2025
Bridging science and law, Westcott will drive MWM’s Life Sciences Practice into the next frontier of biotech and MedTech innovation.
![Organoids without blood vessels can't grow larger than sesame seeds—about 3 millimeters—before dying from lack of oxygen and nutrients. UNT and Stanford researchers say they've solved this problem. Seeds pictured above are not to scale. [Image: Pinchai Puntong/istockphoto]](https://s24806.pcdn.co/wp-content/uploads/2025/08/Sesame-Seed-organoid-science-iStock-1487667097-360x203.jpg)
by Maddie Preston |
Aug 21, 2025
Scientists at at the University of North Texas and Stanford Medicine have created tiny artificial organs called organoids with fully formed blood vessel networks. The stem cell-based breakthrough could transform drug testing and disease research while reducing the need for animal models—and expand possibilities for regenerative medicine.
MORE►
by Quincy Preston |
Feb 20, 2025
The new center at Bridge Labs will train the workforce powering North Texas’ biotech boom—helping startups speed therapies, vaccines, and breakthrough biologics from lab bench to patients. Funded in part by Lyda Hill Philanthropies, the National Center for Therapeutics Manufacturing Satellite Campus is set to open this summer.
MORE►
by Lance Murray |
Dec 9, 2024
Baltimore-based Secretome—which has a presence at BioLabs at Pegasus Park in Dallas and offices in Plano—said the financing will enable it to initiate clinical trials for its lead asset, STM-01, and further advance its drug development pipeline.
MORE►
Dallas-Fort Worth Biotech Targets Cancer’s ‘Achilles Heel’ with Nanotechnology
by Nicole Ward, DRC Data Journalist | Aug 1, 2024
OncoNano's innovative approach to cancer treatment leverages nanotechnology to bring tumors into the light.
MORE►
by Quincy Preston |
Sep 18, 2023
The deal with Fresenius Kabi aims to bring innovative cell and gene treatments closer to patients by advancing Lupagen’s proprietary cell and gene therapy delivery system, the companies said. Their "to the bedside" approach could help open cutting-edge treatments to local hospitals and patients worldwide.
MORE►
by Quincy Preston |
Sep 1, 2023
Tarleton State University received the go-ahead for a new biotechnology institute as part of Texas A&M-Fort Worth’s burgeoning downtown research campus.
Approved in mid-August by the Texas A&M University System Board of Regents, the biotech institute is situated in one of the nation’s fastest-growing life sciences hubs....
MORE►
by Lance Murray |
Aug 3, 2023
Dallas-based Secretome Therapeutics announced that Deepa Prasad has been appointed chief financial officer of the biotechnology company, which develops first-in-class therapeutics derived from neonatal mesenchymal stem cells for the treatment of underserved diseases.
“Deepa brings a wealth of knowledge through her combination of investment banking, operations, and venture capital experience in the life science industry,” Vinny Jindal, president and chief executive officer of Secretome Therapeutics, said in a statement....
MORE►
Newly appointed Visiox Pharma advisor, Vicente Anido Jr. [Courtesy]
Nanoscope Therapeutics Bolsters Board with Addition of Ophthalmic Veteran as Strategic Adviser
by Lance Murray | Mar 22, 2023
Nanoscope Therapeutics has enlisted the expertise of Vicente Anido Jr., Ph.D. to help the company advance its goal of developing sight-restoring gene therapies for retinal degenerative diseases. Anido's appointment as a strategic adviser is expected to support Nanoscope's clinical and corporate strategies, especially as the company progresses towards the potential commercialization of MCO-010.
MORE►
by Lance Murray |
Dec 8, 2022
Southlake-based Renibus Therapeutics—a clinical-stage biotech company developing innovative products for cardiorenal diseases—has received $33 million in bridge financing to help it advance three drugs in its pipeline. The drugs are currently in various phases of trials.
MORE►
![R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]](https://s24806.pcdn.co/wp-content/uploads/2020/04/TayshaGene-Session-970-1-360x203.jpg)
by Kevin Cummings |
Oct 25, 2022
The investment by Tokyo-based Astellas Pharma gives it a 15% stake in Taysha and positions it to potentially purchase the company, according to the Dallas Morning News. The Dallas-based biotech firm's pipeline includes the "first-and-only" gene therapy in clinical development for Rett syndrome and a Phase 1/2 development of a treatment for an inherited nervous system disorder that's awaiting regulatory feedback.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Session II says.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Session II says.
MORE►
[Image: Oleksandr Bushko/istockphoto]
UTSW Scientist: ‘We Need More Women Thinking Creatively in the Lab and Pushing Science Forward’
by Quincy Preston | Oct 8, 2020
This year's Nobel Prize in Chemistry, awarded to two female scientists for the development of CRISPR as a gene-editing tool, is a revolution, according to a pair of UTSW scientists.
UTSW's Eric Olson and Rhonda Bassel-Duby use the technology in their work to treat Duchenne muscular dystrophy. Olson also is the co-founder of biotech Exonics Therapeutics, which exited last year in a deal roughly valued at $1B.
MORE►
by Alex Edwards |
Sep 22, 2020
CEO Brandom Gengelbach says he’s doing business differently in the fast-growing city “where the West begins.”
MORE►
![At the Fourth Annual iC3 Life Science Summit at UT Arlington on Oct. 10, 2017 recipient Lyda Hill will present the award. To register for the summit, visit www.bionorthtx.org. [Illustration: bestbrk/istockphoto]](https://s24806.pcdn.co/wp-content/uploads/2018/09/Bionorthconcept_970_bestbrk_istockphotovector-molecule-background-genetic-and-chemical-compounds-abstract-vector-id908258902-360x203.jpg)
by Quincy Preston |
Sep 22, 2020
Networking—always a highlight of the biotech event— is still a cornerstone thanks to a new virtual conference platform, its organizers said.
MORE►
by Alex Edwards |
Sep 17, 2020
Eyevance Pharmaceuticals, which develops and commercializes ophthalmic products, has been purchased for $225 million by Santen, a Japanese leader in ophthalmology. Eyevance will join Santen's U.S. organization.
MORE►
